Wellington Management Group LLP Trims Holdings in ICU Medical, Inc. $ICUI

Wellington Management Group LLP decreased its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 38.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 148,986 shares of the medical instruments supplier’s stock after selling 94,135 shares during the period. Wellington Management Group LLP owned 0.60% of ICU Medical worth $21,841,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Allworth Financial LP bought a new stake in ICU Medical during the 2nd quarter valued at about $26,000. Hilton Head Capital Partners LLC purchased a new stake in ICU Medical during the fourth quarter valued at approximately $32,000. Public Employees Retirement System of Ohio purchased a new stake in shares of ICU Medical in the 2nd quarter worth $51,000. Covestor Ltd increased its position in ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 126 shares in the last quarter. Finally, Strs Ohio increased its holdings in ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after acquiring an additional 300 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Stock Performance

Shares of NASDAQ:ICUI opened at $167.58 on Monday. The company has a market capitalization of $4.19 billion, a price-to-earnings ratio of 142.02, a price-to-earnings-growth ratio of 2.12 and a beta of 0.75. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56. ICU Medical, Inc. has a 52 week low of $112.50 and a 52 week high of $192.85. The firm has a 50 day moving average of $167.35 and a 200 day moving average of $144.86.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The company had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same quarter last year, the company earned $2.10 earnings per share. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, sell-side analysts predict that ICU Medical, Inc. will post 7.19 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Ben Sousa sold 2,250 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total value of $401,220.00. Following the completion of the transaction, the insider directly owned 3,076 shares of the company’s stock, valued at $548,512.32. This trade represents a 42.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Virginia Sanzone sold 4,856 shares of the firm’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $168.69, for a total transaction of $819,158.64. Following the completion of the transaction, the vice president directly owned 14,604 shares of the company’s stock, valued at approximately $2,463,548.76. This represents a 24.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 21,830 shares of company stock worth $3,905,003. Company insiders own 2.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Raymond James Financial reissued a “strong-buy” rating and set a $200.00 price target on shares of ICU Medical in a report on Friday, August 7th. KeyCorp boosted their price target on shares of ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 21st. Sanford C. Bernstein downgraded ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Wall Street Zen raised shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, BTIG Research increased their price target on ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, ICU Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $192.80.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.